TS-075167 — PROBLEM CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…

TS-075162 — THE PROBLEM Despite advances in classical Hodgkin’s Lymphoma (cHL) treatment, significant challenges persist with up to 40% of patients relapsing after first-line therapy and 50% after autologous stem cell transplant (aSCT). Current therapies like brentuximab vedotin and checkpoint inhibitors…